Peritransplantation Use of Ruxolitinib in Myelofibrosis
Authors:
Open Access
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (12) , 2177-2180
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of RuxolitinibFrontiers in Oncology, 2019
- Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosisBone Marrow Transplantation, 2019
- Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 StudyTransplantation and Cellular Therapy, 2019
- Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell TransplantationTransplantation and Cellular Therapy, 2018
- Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosisEuropean Journal of Haematology, 2018
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analysesJournal of Hematology & Oncology, 2017
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsTransplantation and Cellular Therapy, 2016
- JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosisLeukemia, 2014
- Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinibBone Marrow Transplantation, 2013
- Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC)British Journal of Haematology, 2010